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Abstract 
Aim: To assess the safety and tolerability of switching between subcutaneous 
(SC) and intravenous (IV) trastuzumab in the PrefHer study (NCT01401166). 
Patients and methods: Patients with HER2-positive early breast cancer 
completed (neo)adjuvant chemotherapy and were randomised to receive four 
cycles of SC trastuzumab, via single-use injection device (SID; Cohort 1) or 
hand-held syringe (Cohort 2), followed by four cycles of IV, or vice versa (the 
crossover period presented here) as part of their 18 standard cycles of 
adjuvant trastuzumab treatment. Adverse events (AEs) were reported using 
standard criteria. 
Results: Overall, fewer AEs were reported during the IV treatment periods, 
regardless of administration sequence (IV→SC or SC→IV). Differences in 
AEs between the SC and IV periods were partly due to variances in grade 1 
and 2 local injection site reactions (ISRs) and systemic administration-related 
reactions (ARRs) and these occurred mainly during SC treatment, as 
expected. When ISRs and ARRs were excluded, rates of AEs were higher 
during the first treatment period, compared with the second, in both treatment 
sequences; otherwise there was no clear pattern in the type of AEs reported. 
Rates of clinically important events, including grade ≥3 AEs, serious AEs, AEs 
leading to study drug discontinuation and cardiac AEs, were low and similar 
between treatment arms (<5%). There were no grade 4 or 5 AEs. No new 
safety signals for trastuzumab were observed. 
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Conclusions: PrefHer revealed that switching from IV to SC trastuzumab 
(hand-held syringe or SID) or vice versa did not impact the known safety 
profile of trastuzumab. 
Word Count: 250/250 words 
Keywords for indexing: Breast cancer; HER2/neu; Intravenous; 
Subcutaneous; Trastuzumab; Patient preference [The Breast limit is 6] 
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Introduction 
Trastuzumab (Herceptin®, F. Hoffmann-La Roche Ltd, Basel, Switzerland), is 
the standard of care for treating human epidermal growth factor receptor 2 
(HER2)-positive breast cancer [1–3] and can be administered by intravenous 
(IV) infusion or subcutaneous (SC) injection. SC trastuzumab (Herceptin® SC, 
F. Hoffmann-La Roche Ltd) contains the recombinant human hyaluronidase 
enzyme as an excipient and offers a fixed-dose alternative to the conventional 
weight-adjusted IV dose. SC trastuzumab was approved by the European 
Medicines Agency based on data from the phase III, open-label, randomised, 
international HannaH study (NCT00950300) [4,5].  
HannaH compared SC and IV trastuzumab in terms of pharmacokinetics, 
efficacy and safety in the neoadjuvant–adjuvant setting [4,5]. Analysis of the 
co-primary endpoints, serum trough concentration (Ctrough) and pathological 
complete response (pCR), demonstrated that SC trastuzumab was non-
inferior to IV [4]. Despite similar overall safety profiles, a numerical difference 
was reported in the rate of serious adverse events (SAEs) [4,5]. This 
imbalance was not reflected in the distribution of grade 3–5 AEs, and despite 
systematic analyses an underlying clinical explanation could not be identified 
[4,5]. An SC trastuzumab single-use injection device (SID) demonstrates 
pharmacokinetic bioequivalence with the hand-held syringe method [6].  
Patients’ preferences, for either SC administration or IV infusion, were 
investigated in the international, open-label, randomised, two-cohort, two-arm, 
PrefHer study (NCT01401166) in HER2-positive early breast cancer [7–9]. 
PrefHer incorporated a unique crossover period, comprising four cycles of SC 
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trastuzumab followed by four cycles of IV, or vice versa. This study design 
allowed a direct comparison of patients’ preferences for SC or IV trastuzumab 
and evaluation of the safety profile associated with multiple, sequential 
administrations.  
When compared with the known safety profile of IV trastuzumab, previous 
analyses from both cohorts of PrefHer indicated that SC trastuzumab was well 
tolerated, with no new safety signals [7–9]. Although an increase in clinician-
reported AEs was noted with SC trastuzumab, this was not the case for 
patient-reported events [7,9]. Differences between AE rates in the combined 
SC and IV periods (Cohorts 1 and 2) were driven by grade 1 events and 
occurred more frequently during the SC period [7,9]. However, patients 
preferred SC over IV trastuzumab regardless of SID or hand-held syringe 
delivery, and patients reported SC trastuzumab to be less painful and to 
cause less bother from bruising or irritation than IV [7–9]. 
With consistent patient preference for SC over IV trastuzumab and the 
European approval of SC trastuzumab, patients may opt to switch from IV to 
SC trastuzumab during their treatment for early breast cancer. Due to its 
unique design, the PrefHer study offered the opportunity to assess the safety 
profile of patients switching between IV and SC trastuzumab, considering not 
only the influence of the treatment sequence, but also the impact of previous 
exposure to IV trastuzumab during (neo)adjuvant treatment. We report the 
results of this analysis here.  
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Patients and methods 
Patients and study treatment 
After completion of surgery and neoadjuvant or adjuvant chemotherapy, 
patients were randomised to receive four cycles of SC trastuzumab followed 
by four cycles of IV trastuzumab, or vice versa (the crossover period 
assessed here; Fig. 1) [7–9]. Patients then received trastuzumab to complete 
their standard 18 cycles of adjuvant treatment, planned to be via IV or SC SID 
in Cohort 1 and SC hand-held syringe in Cohort 2. Since (neo)adjuvant 
treatment could have included prior IV trastuzumab, randomisation was 
stratified by de novo (trastuzumab-naïve) or non-de novo (already receiving IV 
trastuzumab) treatment. Patients were enrolled if they still had at least eight 
out of their 18 planned cycles of trastuzumab remaining. 
SC trastuzumab was administered either via SID (Cohort 1) or hand-held 
syringe (Cohort 2) and given every 3 weeks at a fixed dose of 600 mg, with no 
loading dose required. IV trastuzumab was administered every 3 weeks at a 
loading dose of 8 mg/kg (if the patient was not already receiving trastuzumab 
and was randomised to receive IV trastuzumab as the first cycle of treatment), 
followed by maintenance doses of 6 mg/kg.  
The primary endpoint, previously reported, was the proportion of patients 
indicating an overall preference for SC or IV trastuzumab administration [7,9]. 
Secondary endpoints included safety and tolerability [7–9]. 
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PrefHer was conducted in accordance with Good Clinical Practice guidelines 
and the Declaration of Helsinki. All patients provided written informed consent. 
Approval for the protocol was obtained from appropriate local and national 
independent ethics committees. 
Assessment of switching between SC and IV trastuzumab 
AEs that occurred during the crossover period were summarised according to 
the primary system-organ class (SOC), and within each SOC by Medical 
Dictionary for Regulatory Activities (MedDRA)-preferred term; including 
overall AEs, grade ≥3 AEs, SAEs, systemic administration-related reactions 
(ARRs), localised injection site reactions (ISRs), AEs leading to 
discontinuation and cardiac AEs. AE incidences were summarised by 
treatment sequence (IV→SC or SC→IV) and route of administration (SC or 
IV); rates of AEs were then summarised by cohort (Cohort 1 or 2 and 
combined) and de novo or non-de novo trastuzumab. Analyses either 
included or excluded ARRs and ISRs. 
AEs, SAEs and cardiac AEs were graded and reported according to the 
National Cancer Institute Common Terminology Criteria for Adverse Events 
(NCI-CTCAE V4.0), International Conference on Harmonisation E2A guidance 
documentation (ICH E2A) and the New York Heart Association functional 
classification criteria, respectively.  
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Statistical considerations 
Adverse event data are presented for the safety population, i.e., all patients 
who received ≥1 dose of trastuzumab during the crossover period. Data 
shown are the pooled (Cohort 1 [SID] and Cohort 2 [hand-held syringe]) or 
individual safety data from both cohorts during the crossover period. Results 
are descriptive. 
AEs and patients’ preferences were compared in the evaluable intention-to-
treat (ITT) population (patients who completed both interviews and had ≥1 
administration of both SC and IV trastuzumab).  
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Results 
Patients 
Baseline patient demographics, tumour characteristics and treatment histories 
of patients enrolled in Cohorts 1 and 2 of PrefHer have been reported 
previously [7–9]. A total of 488 patients (Cohorts 1 and 2 pooled), from 12 
countries and 74 sites, participated, and the evaluable ITT population included 
235 patients randomised to receive SC followed by IV (SC→IV arm), and 232 
to receive IV followed by SC (IV→SC arm) (Fig. 2) [7–9]. The safety 
population comprised 483 patients (five randomised patients did not receive 
study treatment); most patients (459/483 [95.0%]) completed all eight cycles 
[7–9]. Of the safety population patients, 243 were randomised to receive four 
cycles of SC→IV trastuzumab, and 240 patients the alternate sequence. Of 
these, 242 patients were treated with SC trastuzumab using the SID and 237 
using the hand-held syringe; 24 patients completed <8 cycles during the 
crossover period [9]. The majority of patients had prior trastuzumab treatment 
(194/243 [79.8%] in the SC→IV arm and 191/240 [79.6%] in the IV→SC arm). 
Safety analysis during the crossover period (pooled cohorts) 
Overall, the safety profiles of the pooled cohorts were similar between SC and 
IV trastuzumab during the crossover period, with no new safety signals 
observed (Table 1) [7–9].  
Within the SC→IV arm, the rate of AEs during SC treatment was 65.4% 
(159/243 patients), compared with 48.7% during IV treatment (116/238 
patients). The incidence of grade ≥3 AEs was 4.5% (11/243 patients) during 
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SC treatment and 2.9% (7/238 patients) during IV treatment. While there were 
a number of SOCs that were reported more frequently during SC 
administration (Table 2), the only preferred terms that accounted for any 
difference between treatment cycles were ISRs and ARRs (based on all AEs 
reported). Excluding ISRs and ARRs, the rate of AEs was 59.7% (145/243) 
during the SC period and 47.9% (114/238) during the IV period. 
Among patients in the IV→SC arm, the rates of AEs were similar when 
switching from IV (129/240 [53.8%] patients) to SC (133/236 [56.4%] patients; 
Table 1). The incidence of grade ≥3 AEs was 2.1% (5/236 patients) during SC 
and 3.8% (9/240 patients) during IV treatment. When ISRs and ARRs were 
excluded, the rate of AEs was higher during IV (126/240 [52.5%]) than SC 
treatment (111/236 [47.0%]). ARR rates were similar between IV and SC.  
Overall, the majority of ARRs were grade 1 or 2 and the frequency of grade 3 
ARRs in both treatment arms was low (<2% in the SC→IV arm and <1% in 
the IV→SC arm). ISRs were observed exclusively during the SC periods in 
both treatment arms, except in one patient in the IV→SC arm who 
experienced an ISR during IV treatment (Table 1). 
The proportion of patients experiencing a clinically important event, including 
grade ≥3 AEs, SAEs, AEs leading to study drug discontinuation or cardiac 
AEs, was similar between treatment groups (Table 1). Overall, eight patients 
reported nine SAEs during the SC or IV treatment periods (four patients 
during the SC treatment periods and four during the IV treatment periods; 
Table 1) and 11 patients withdrew from treatment due to AEs (five during the 
SC treatment periods and six during the IV treatment periods; Table 1). 
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Cardiac AE rates were low and similar between treatment arms (14 [2.9%] in 
the SC→IV treatment arm and 11 [2.3%] in the IV→SC arm; Table 1). 
Differences in AE rates by grade between the SC and IV periods were 
observed only for grade 1 and 2 AEs (Fig. 3). Grade 3 AEs were reported for 
17 patients (7.0%) in the SC→IV treatment arm (11 [4.5%] during the SC 
period and seven [2.9%] during IV treatment; one patient experienced a grade 
3 AE during SC and IV treatment) and 14 patients (5.8%) in the IV→SC 
treatment arm (nine [3.8%] during SC treatment and five [2.1%] during the IV 
period). No grade 4 or 5 AEs were reported (Fig. 3) [7–9].  
Safety analysis during the crossover period (individual cohorts) 
Comparison of the SID and hand-held syringe methods of administering SC 
trastuzumab revealed a similar pattern of clinically important AEs to the 
overall analysis (Tables 3 and 4). No new safety signals specific to either 
method were observed. 
AE rates in patients de novo or non-de novo for trastuzumab treatment 
(pooled cohorts) 
The majority of patients (n = 385) received prior trastuzumab. Although the 
number of prior cycles varied (1–10), AE rates, excluding ISRs and ARRs for 
patients in each treatment arm, whether de novo or non-de novo for 
trastuzumab treatment, were higher during the first treatment period 
compared with the second, regardless of whether patients received SC or IV 
trastuzumab (Table 5). 
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In the IV→SC arm, AEs rates were similar between the IV and SC treatment 
periods for de novo and non-de novo patients. Patients in the non-de novo 
group reported a higher proportion of AEs for all AE categories compared with 
de novo patients.  
Relationship between patients’ preference and safety 
There was no clear link between grade 3 and grade 1–2 AEs and patients’ 
preferences for SC or IV trastuzumab (Supplementary Table 1). As 
previously reported, patients overwhelmingly preferred SC administration of 
trastuzumab [7–9]. 
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Discussion 
Trastuzumab has improved the prognosis of patients with HER2-positive 
breast cancer in both early and metastatic disease [12,13]. One year of 
trastuzumab is the standard of care in the adjuvant setting, providing 
consistent improvements in disease-free and overall survival [14,15]. The 
HannaH study compared SC and IV trastuzumab and reported that SC was 
non-inferior to IV in terms of pCR and Ctrough; safety was similar [4,5]. 
Previously published PrefHer analyses found that SC trastuzumab was well 
tolerated and that patients preferred it over IV administration [7–9]. The 
SafeHer study (NCT01566721) showed consistent safety results with the 
hand-held syringe; SID data are anticipated [16].  
Overall, the results from PrefHer’s crossover period demonstrated a 
consistent safety profile with the known safety profile of IV trastuzumab [17]. 
This analysis revealed no clinically relevant differences when patients 
switched between trastuzumab routes. While fewer AEs were reported during 
the IV treatment periods regardless of sequence (IV→SC or SC→IV), when 
ISRs and ARRs were excluded the rate of AEs was higher during the first 
period, compared with the second, in both treatment arms. Importantly, when 
switching from IV→SC, the frequency of clinically important events (grade ≥3 
AEs, SAEs, AEs leading to trial drug discontinuation and cardiac AEs) was 
<5% and similar between treatment arms. Differences in grade 1 and 2 AEs 
between the SC and IV periods were partly due to variances in ISRs and 
ARRs. These occurred mainly during SC treatment, as expected; otherwise, 
there was no clear pattern in the types of AEs reported.  
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The higher proportion of overall AEs in the non-de novo group could be 
explained by imbalanced subgroup sizes (de novo patients comprised 20% of 
the population). Also, considering that there were more AEs at the injection 
site with SC trastuzumab, particularly at the initiation of treatment, it is logical 
that these AEs are more marked during SC→IV treatment. Regardless, the 
important elements are that grade ≥3 AE rates were balanced, and that 
patients expressed a preference for SC trastuzumab regardless of whether 
they had received prior trastuzumab treatment [9]. As such, the difference in 
AE rates between de novo and non-de novo groups has no clinical impact. 
Combining the SC SID and hand-held syringe cohorts for the switching 
analysis was considered appropriate as the SID is pharmacokinetically 
bioequivalent to the hand-held syringe [6]. AE profiles for the individual 
cohorts were generally similar to those observed for the pooled cohorts. 
Previously reported analyses from PrefHer demonstrated that patients 
preferred SC trastuzumab, regardless of SID or hand-held syringe delivery [7–
9]. The current analysis did not find any clear differences in AE profiles 
between the SID and the hand-held syringe.  
This analysis was a safety review of the crossover period of PrefHer (four 
cycles of SC and four cycles of IV trastuzumab), and therefore does not take 
into consideration the overall safety profile. Following the crossover period, 
patients completed their remaining trastuzumab treatment (up to 18 cycles), 
and therefore AEs that may emerge with late onset are not reported.  
Where several formulations may be available for the same drug, patient 
experience and preference may significantly affect treatment adherence and 
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quality of life [18]. Patient preference is particularly pertinent when considering 
IV versus SC administration [18]. Among trials that compared IV and SC 
routes of administration of the same drug, only two had patient preference as 
the primary objective: PrefHer [7–9] and SWITCH [19]. The SWITCH trial 
compared elective switching (IV→SC) between two anti-tumour necrosis 
factor treatments, adalimumab and infliximab, in Crohn’s disease [19]. 
Overall, a clear preference for SC treatment was reported by patients in both 
studies [7–9,19]. European approval of SC trastuzumab, in combination with 
overwhelming patient preference, suggests that patients may opt to switch 
from IV to SC trastuzumab in early breast cancer. The results of this analysis 
demonstrate that AE rates were similar when switching from IV to SC 
trastuzumab, with no new safety concerns. 
In conclusion, during the crossover period, the PrefHer study demonstrated 
no clinically relevant safety differences when patients switched from IV to SC 
trastuzumab, or vice versa. PrefHer is the only study to provide prospective 
data on switching from IV→SC treatment and the data from this trial support 
switching in clinical practice.  
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Highlights 
 We assessed switching between subcutaneous (SC) and intravenous 
(IV) trastuzumab. 
 Patients received 4 cycles of SC then 4 cycles of IV trastuzumab, or 
vice versa. 
 Rates of clinically important events were low and similar (IV→SC 
versus SC→IV). 
 No new safety signals for trastuzumab were observed. 
 Switching did not impact the known trastuzumab early breast cancer 
safety profile. 
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Fig. 1. PrefHer study design 
 
Includes optional time-and-motion sub-study in both cohorts [10,11]. Patients completed 
surgery and (neo)adjuvant chemotherapy (concurrent or sequential with IV trastuzumab) 
and had at least eight out of the total of 18 planned trastuzumab cycles remaining in their 
adjuvant trastuzumab therapy. Stratification factor: de novo versus non-de novo 
trastuzumab (to balance the sequence groups for the proportion of patients with prior IV 
trastuzumab treatment). * * Reprinted from The Lancet Oncology, 14: Pivot X, Gligorov J, 
Müller V, Barrett-Lee P, Verma S, Knoop A, Curigliano G, Semiglazov V, López-Vivanco 
G, Jenkins V, Scotto N, Osborne S, Fallowfield L; PrefHer Study Group. Preference for 
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subcutaneous or intravenous administration of trastuzumab in patients with HER2-
positive early breast cancer (PrefHer): an open-label randomised study, 962e970, 
Copyright (2013), with permission from Elsevier. † In the SID cohort, remaining 
trastuzumab was administered by IV infusion unless patients participated in SID self-
administration. In the hand-held syringe cohort, remaining trastuzumab was planned to be 
administered subcutaneously by hand-held syringe. Abbreviations: HER2, human 
epidermal growth factor receptor 2; IV, intravenous; PINT, patient interview; R, 
randomised; SC, subcutaneous; SID, single-use injection device. 
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Fig. 2. PrefHer enrolment and allocation (pooled cohorts; safety 
population) 
 
* No treatment was given on-trial as patient was screened and randomised but was 
later found to have an LVEF of 53%. † Patients who received at least one dose of 
study treatment. ‡ Three patients in non-de novo group (one in the SID cohort and 
two in the HHS cohort) and one patient in the de novo group (SID cohort) 
discontinued IV trastuzumab during IV→SC treatment. Abbreviations: HHS, hand-held 
syringe; IV, intravenous; LVEF, left ventricular ejection fraction; SC, subcutaneous; SID, 
single-use injection device. 
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Fig. 3. Adverse events by NCI-CTCAE grade in patients switching between 
trastuzumab administration routes during the crossover period  
(pooled cohorts; safety population) 
 
All AEs, including SAEs, are included. If an AE start date was partially or fully 
missing, and it was unclear during which treatment period the AE started, the AE was 
assigned to all relevant treatment periods. If a patient had multiple events of the 
same NCI-CTCAE grade or relationship category, they were counted only once in 
that NCI-CTCAE grade or relationship category. AEs (all NCI-CTCAE grades) were 
reported in 65.4% (n = 159; Arm A: Cycles 1–4 SC), 48.7% (n = 116; Arm A: Cycles 
5–8 IV), 53.8% (n = 129; Arm B: Cycles 1–4 IV) and 56.4% (n = 133; Arm B: Cycles 
5–8 SC) of patients, respectively. Data was missing from 0.8% (n = 2; Arm A: Cycles 
1–4 SC), 0.4% (n = 1; Arm B: Cycles 1–4 IV) and 0.8% (n = 2; Arm B: Cycles 5–8 
SC) of patients, respectively. Abbreviations: AE, adverse event; IV, intravenous; 
NCI-CTCAE, National Cancer Institute Common Terminology Criteria for Adverse 
Events; SAE, serious adverse event; SC, subcutaneous. 
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Table 1 Clinically relevant adverse events in patients switching between trastuzumab administration routes during the crossover 
period (pooled cohorts; safety population) 
 
SCIV IVSC 
Cycles 1–4: SC 
N = 243 
n (%) 
Cycles 5–8: IV 
N = 238 
n (%) 
Cycles 1–4: IV 
N = 240 
n (%) 
Cycles 5–8: SC 
N = 236 
n (%) 
AEs 159 (65.4) 116 (48.7) 129 (53.8) 133 (56.4) 
AEs grade ≥3 11 (4.5) 7 (2.9) 9 (3.8) 5 (2.1) 
SAEs 3 (1.2) 2 (0.8) 2 (0.8) 1 (0.4) 
Systemic ARRs 39 (16.0) 12 (5.0) 18 (7.5) 18 (7.6) 
Localised ISRs 57 (23.5) 0 1 (0.4) 40 (16.9) 
AEs excluding ISRs and ARRs 145 (59.7) 114 (47.9) 126 (52.5) 111 (47.0) 
AEs leading to study drug 
discontinuation 3 (1.2) 4 (1.7) 2 (0.8) 2 (0.8) 
Cardiac AEs 6 (2.5) 8 (3.4) 6 (2.5) 5 (2.1) 
If an AE start date was partially or fully missing, and it was unclear during which treatment period the AE started, the AE was assigned to all relevant 
treatment periods. 
Abbreviations: AE, adverse event; ARR, administration-related reaction; ISR, injection site reaction; IV, intravenous; SAE, serious adverse event; SC, 
subcutaneous. 
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Table 2 Adverse events by SOC and specific adverse event in ≥5% of patients (any group) when switching between trastuzumab 
administration routes during the crossover period (pooled cohorts; safety population) 
 
SCIV IVSC 
Cycles 1–4: SC 
N = 243 
n (%) 
Cycles 5–8: IV 
N = 238 
n (%) 
Cycles 1–4: IV 
N = 240 
n (%) 
Cycles 5–8: SC 
N = 236 
n (%) 
Musculoskeletal and connective 
tissue disorders 
43 (17.7) 27 (11.3) 35 (14.6) 38 (16.1) 
 Arthralgia 10 (4.1) 11 (4.6) 16 (6.7) 14 (5.9) 
General disorders and 
administration site conditions 
87 (35.8) 31 (13.0) 38 (15.8) 58 (24.6) 
 Asthenia 16 (6.6) 10 (4.2) 13 (5.4) 11 (4.7) 
 Fatigue 14 (5.8) 8 (3.4) 10 (4.2) 5 (2.1) 
Infections 25 (10.3) 35 (14.7) 23 (9.6) 16 (6.8) 
Gastrointestinal disorders 33 (13.6) 25 (10.5) 17 (7.1) 25 (10.6) 
 Nausea 16 (6.6) 9 (3.8) 5 (2.1) 9 (3.8) 
Nervous system disorders 32 (13.2) 21 (8.8) 20 (8.3) 17 (7.2) 
 Headache 13 (5.3) 4 (1.7) 12 (5.0) 7 (3.0) 
Vascular disorders 31 (12.8) 16 (6.7) 19 (7.9) 22 (9.3) 
 Hot flush 17 (7.0) 10 (4.2) 6 (2.5) 6 (2.5) 
Skin and SC tissue disorders 45 (18.5) 18 (7.6) 29 (12.1) 23 (9.7) 
Respiratory, thoracic and 
mediastinal disorders 
21 (8.6) 12 (5.0) 10 (4.2) 8 (3.4) 
Injury, poisoning and procedural 13 (5.3) 9 (3.8) 9 (3.8) 2 (0.8) 
 29 
 
complications 
All AEs, including SAEs, were included. If an AE start date was partially or fully missing, and it was unclear during which treatment period the AE started, the 
AE was assigned to all relevant treatment periods. 
Abbreviations: AE, adverse event; IV, intravenous; SAE, serious adverse event; SC, subcutaneous; SOC, system-organ class. 
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Table 3 Clinically relevant adverse events in patients switching between trastuzumab administration routes during the crossover 
period (Cohort 1; safety population) 
 
SC SIDIV IVSC SID 
Cycles 1–4: SC SID 
N = 122 
n (%) 
Cycles 5–8: IV 
N = 119 
n (%) 
Cycles 1–4: IV 
N = 122 
n (%) 
Cycles 5–8: SC SID 
N = 120 
n (%) 
AEs 77 (63.1) 47 (39.5) 68 (55.7) 68 (56.7) 
AEs grade ≥3 5 (4.1) 2 (1.7) 3 (2.5) 2 (1.7) 
SAEs 3 (2.5) 1 (0.8) 1 (0.8) 1 (0.8) 
Systemic ARRs 17 (13.9) 2 (1.7) 9 (7.4) 7 (5.8) 
Localised ISRs 29 (23.8) 0 0 19 (15.8) 
AEs excluding ISRs and ARRs 68 (55.7) 46 (38.7) 66 (54.1) 56 (46.7) 
AEs leading to study drug 
discontinuation 2 (1.6) 
0 1 (0.8) 0 
Cardiac AEs 3 (2.5) 3 (2.5) 2 (1.6) 3 (2.5) 
If an AE start date was partially or fully missing, and it was unclear during which treatment period the AE started, the AE was assigned to all relevant 
treatment periods. 
Abbreviations: AE, adverse event; ARR, administration-related reaction; ISR, injection site reaction; IV, intravenous; SAE, serious adverse event; SC, 
subcutaneous; SID, single-use injection device. 
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Table 4 Clinically relevant adverse events in patients switching between trastuzumab administration routes during the crossover 
period (Cohort 2; safety population) 
 
SC HHSIV IV HHSSC 
Cycles 1–4: SC HHS 
N = 121 
n (%) 
Cycles 5–8: IV 
N = 119 
n (%) 
Cycles 1–4: IV 
N = 118 
n (%) 
Cycles 5–8: SC HHS 
N = 116 
n (%) 
AEs 82 (67.8) 69 (58.0) 61 (51.7) 65 (56.0) 
AEs grade ≥3 6 (5.0) 5 (4.2) 6 (5.1) 3 (2.6) 
SAEs 0 1 (0.8) 1 (0.8) 0 
Systemic ARRs 22 (18.2) 10 (8.4) 9 (7.6) 11 (9.5) 
Localised ISRs 28 (23.1) 0 1 (0.8) 21 (18.1) 
AEs excluding ISRs and ARRs 77 (63.6) 68 (57.1) 60 (50.8) 55 (47.4) 
AEs leading to study drug 
discontinuation 1 (0.8) 4 (3.4) 1 (0.8) 2 (1.7) 
Cardiac AEs 3 (2.5) 5 (4.2) 4 (3.4) 2 (1.7) 
If an AE start date was partially or fully missing, and it was unclear during which treatment period the AE started, the AE was assigned to all relevant 
treatment periods.  
Abbreviations: AE, adverse event; ARR, administration-related reaction; HHS, hand-held syringe; ISR, injection site reaction; IV, intravenous; SAE, serious 
adverse event; SC, subcutaneous. 
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Table 5 Adverse events in patients de novo or non-de novo for trastuzumab administration prior to the crossover period (pooled 
cohorts; safety population) 
Overall safety population 
SCIV IVSC 
Cycles 1–4: SC 
N = 243 
n (%) 
Cycles 5–8: IV 
N = 238 
n (%) 
Cycles 1–4: IV 
N = 240 
n (%) 
Cycles 5–8: SC 
N = 236 
n (%) 
AEs excluding ISRs and ARRs 145 (59.7) 114 (47.9) 126 (52.5) 111 (47.0) 
AEs grade ≥3 11 (4.5) 7 (2.9) 9 (3.8) 5 (2.1) 
SAEs 3 (1.2) 2 (0.8) 2 (0.8) 1 (0.4) 
 
De novo treatment 
SCIV IVSC 
Cycles 1–4: SC 
N = 49 
n (%) 
Cycles 5–8: IV 
N = 47 
n (%) 
Cycles 1–4: IV 
N = 49 
n (%) 
Cycles 5–8: SC 
N = 48 
n (%) 
AEs excluding ISRs and ARRs 21 (42.9) 14 (29.8) 17 (34.7) 16 (33.3) 
AEs grade ≥3 1 (2.0) 1 (2.1) 1 (2.0) 1 (2.1) 
SAEs 0 1 (2.1) 0 0 
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Non-de novo treatment 
SCIV IVSC 
Cycles 1–4: SC 
N = 194 
n (%) 
Cycles 5–8: IV 
N = 191 
n (%) 
Cycles 1–4: IV 
N = 191 
n (%) 
Cycles 5–8: SC 
N = 188 
n (%) 
AEs excluding ISRs and ARRs 124 (63.9) 100 (52.4) 109 (57.1) 95 (50.5) 
AEs grade ≥3 10 (5.2) 6 (3.1) 8 (4.2) 4 (2.1) 
SAEs 3 (1.5) 1 (0.5) 2 (1.0) 1 (0.5) 
If an AE start date was partially or fully missing, and it was unclear during which treatment period the AE started, the AE was assigned to all relevant 
treatment periods. 
Abbreviations: AE, adverse event; ARR, administration-related reaction; ISR, injection site reaction; IV, intravenous; SAE, serious adverse event; SC, 
subcutaneous. 
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Appendix A. Supplementary data 
Supplementary Table 1: Comparison of adverse events and patients’ preferred method of administration during the 
crossover period (pooled cohorts; ITT population) 
Grade 3 AEs 
Preference 
AE experienced during SC or IV period 
IV and SC 
N = 1 
n (%) 
SC only 
N = 11 
n (%) 
IV only 
N = 13 
n (%) 
Neither 
N = 442 
n (%) 
IV 0 3 (27.3) 2 (15.4) 40 (9.0) 
SC 1 (100.0) 8 (72.7) 11 (84.6) 395 (89.4) 
No preference 0 0 0 7 (1.6) 
 
Grade ≤2 AEs 
Preference 
AE experienced during SC or IV period 
IV and SC 
N = 175 
n (%) 
SC only 
N = 104 
n (%) 
IV only 
N = 57 
n (%) 
Neither 
N = 131 
n (%) 
IV 22 (12.6) 7 (6.7) 4 (7.0) 12 (9.2) 
SC 150 (85.7) 97 (93.3) 50 (87.7) 118 (90.1) 
No preference 3 (1.7) 0 3 (5.3) 1 (0.8) 
Abbreviations: AE, adverse event; IV, intravenous; ITT, intention-to-treat; SC, subcutaneous. 
 
